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Risk of advanced diabetic nephropathy in type 1 diabetes is [1–4] and may contribute to the development of diabetic
associated with endothelial nitric oxide synthase gene polymor- nephropathy [4, 5] and premature atherosclerosis [6].
phism. This abnormality results from a decreased availability ofBackground. Polymorphisms in the endothelial nitric oxide
nitric oxide (NO), which can be caused by impaired NOsynthase gene (eNOS) may be implicated in the development
synthesis or to increased NO inactivation [7, 8].of nephropathy in patients with type 1 or insulin-dependent
diabetes mellitus (IDDM). Synthesis of NO is catalyzed by three NO synthases:
Methods. Three groups of IDDM patients were selected to endothelial, neuronal, and inducible [9]. Encoded by sep-
study this hypothesis: cases with advanced diabetic nephropa- arate genes, each isoform has a distinct pattern of expres-thy (N 5 78), cases with overt proteinuria but normal serum
sion in tissues [10]. The endothelial NO synthase genecreatinine (N 5 74), and controls with normoalbuminuria de-
(eNOS) encoding for endothelial NO synthase is a logicalspite 15 years of diabetes (N 5 195). Parents of 132 cases
and 53 controls were also examined and were used for the target for a search for DNA sequence differences that
transmission disequilibrium test, a family-based study design may contribute to endothelial dysfunction and, indi-
to test association. rectly, to the susceptibility to the development of diabeticResults. We examined four eNOS polymorphisms, and two
nephropathy [1–4].were associated with diabetic nephropathy in the case-control
In endothelial cells, eNOS is expressed constitutivelycomparisons: a T to C substitution in the promoter at position
2786 and the a-deletion/b-insertion in intron 4. For the former, [9]. In the basal state, the function of endothelial NO
the risk of developing advanced nephropathy was higher for synthase is modulated by changes in intracellular cal-
C allele homozygotes than for the other two genotypes (odds
cium, allowing an immediate adjustment of NO synthe-ratio 2.8, 95% CI, 1.4 to 5.6). For the latter polymorphism, it
sis. Under certain circumstances, however, the basal levelwas the a-deletion carriers that had the higher risk (odds ratio
2.3, 95% CI, 1.3 to 4.0) in comparison with noncarriers. Both of NO release may be regulated by changes in the expres-
polymorphisms were analyzed together as haplotypes in a fam- sion of eNOS. For example, increased expression of
ily-based study using the transmission disequilibrium test. The eNOS and increased release of NO have been observed
C/a-deletion haplotype was transmitted from heterozygous
following a change in shear stress [11, 12] and duringparents to cases with advanced diabetic nephropathy with a
pregnancy [13, 14].significantly higher frequency than expected (P 5 0.004).
Conclusion. The findings of the case-control and family- The locus for eNOS is on the long arm of chromosome
based studies demonstrate clearly that DNA sequence differ- 7. Recently, this region has been found to be linked
ences in eNOS influence the risk of advanced nephropathy in with diabetic nephropathy in type 2 diabetes mellitustype 1 diabetes.
[abstract; Fogarty et al, Diabetes 48(Suppl 11):A47, 1999]
[15]. During the last few years, several sequence differ-
Endothelial dysfunction is prevalent in patients with ences were identified in eNOS, and their association with
type 1 or insulin-dependent diabetes mellitus (IDDM) various diseases has been explored. A microsatellite in
intron 13 has been examined for linkage with hyperten-
sion, and although the findings were negative in FrenchKey words: gene for NOS, IDDM, DNA sequence, eNOS polymor-
phism, diabetes, endothelium. [16] and American populations [17], they were positive
in a Japanese population [18]. Also, linkage of thisReceived for publication December 21, 1998
marker with the familial occurrence of pregnancy-and in revised form September 15, 1999
Accepted for publication September 15, 1999 induced hypertension has been demonstrated in women
[19]. In intron 4, a variable repeat of a 27 base pairÓ 2000 by the International Society of Nephrology
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consensus sequence has been described, the allele desig- study, we selected and examined patients with persistent
proteinuria or ESRD. This included the 201 such patientsnated “a-deletion” having four repeats and the allele
designated “b-insertion” having five. The a-deletion has enrolled in the follow-up study, of whom 122 have been
examined so far. These were supplemented with 235been found to be associated with coronary artery disease
in smokers [20], with essential hypertension in a Japanese patients of the Joslin Clinic with type 1 diabetes and
persistent proteinuria or ESRD who were not included inpopulation [21], and with end-stage renal disease (ESRD)
in nondiabetic individuals [22]. Thus far, only one poly- the study on natural history of microalbuminuria. From
among this group, 30 patients were examined and usedmorphism affecting transcription of the gene has been
described, a T-786C substitution within the promoter. in this study. Thus, the total number of unrelated cases
examined and enrolled into this study was 152. We pref-The “C” allele is associated with promoter activity that
is less than half that of the “T” allele [23]. The “C” allele erentially selected controls and cases with both parents
living and available for examination.was more frequent in cases with coronary spasm than in
controls [23]. Recently, a polymorphism has been found For the family-based association study, both parents
of 131 cases and 52 controls have been examined so far.in exon 7, a G894T substitution that results in a Glu!Asp
amino acid change at codon 298 [24]. This polymorphism In 37 families, 38 additional siblings with type 1 diabetes
were identified and examined (17 of them were classifiedhas been associated with myocardial infarction, coronary
spasm, and essential hypertension in Japanese popula- as cases and 21 as controls).
Diabetes was considered as type 1 if it was diagnosedtions [24–26].
The aim of this study was to examine whether any of before age of 30 years and treatment with insulin began
within one year of diagnosis and continued thereafter.the known polymorphisms in eNOS are associated with
diabetic nephropathy in IDDM. Because genetic factors Only Caucasian patients with type 1 diabetes were in-
cluded in this study.are often associated with the early or most severe pheno-
types of complex diseases [27–29], we divided the cases
Examination of study participantsof nephropathy into two groups according to severity
for the comparison with controls without nephropathy. After consenting to participate in the study, each sub-
ject underwent a standardized physical examination andThe positive findings from the case-control comparisons
were examined further in a family-based study in which provided a diabetes history regarding its diagnosis, treat-
ment, and the occurrence of complications. Each individ-the haplotypes defined by the two eNOS polymorphisms
could be determined. The haplotypes were tested for ual provided a blood sample for biochemical analysis
and DNA extraction, and a random urine sample forassociation with advanced diabetic nephropathy with the
transmission disequilibrium test (TDT), a test for associ- urinalysis and for determination of the albumin/creati-
nine ratio (ACR). For the family-based study, parentsation that is valid even in the presence of population
stratification or selection biases [30]. provided blood samples for DNA extraction. The Com-
mittee on Human Subjects of the Joslin Diabetes Center
approved the protocol and informed consent forms.
METHODS
Study populations Diagnosis of diabetic nephropathy
Diabetic nephropathy status was determined on theIndividuals for the study were recruited from among
patients attending the Joslin Clinic in the early 1990s. basis of questionnaires, medical records (from the Joslin
Diabetes Center and other institutions), and measure-During 1991 to 1993, a 50% sample of clinic attendees
with IDDM in the age range of 15 to 44 years (N 5 ments of the ACR. The number of ACR measurements
available varied from a minimum of 3 to 27. Methods1613) were enrolled in a follow-up study of the natural
history of microalbuminuria [31]. On the basis of multi- for measuring the ACR have been described previously
[31]. Patients were classified as controls (N 5 195) ifple measurements of the albumin/creatinine ratio (ACR)
in random urine specimens performed during a two- they had diabetes for at least 15 years and the ACR was
less than 20 mg/mg in at least two out of the last threeyear observation period, patients were classified into the
following categories: normoalbuminuria (N 5 1100), urine specimens. Patients with microalbuminuria or in-
termittent proteinuria were excluded from the study.persistent microalbuminuria (N 5 312), and proteinuria
or ESRD (N 5 201) [31]. Patients were considered cases if they had received a
renal transplant or treatment with dialysis due to diabeticAs unrelated controls for this study, we selected pa-
tients with normoalbuminuria and diabetes of at least nephropathy or if they had persistent proteinuria. Persis-
tent proteinuria was defined as two out of the three most15 years duration. Among the 1100 normoalbuminurics,
420 patients met this additional criterion, and 195 of recent urinalyses positive for macroalbuminuria, either
by reagent strip ($1 1 on Multistix; Ames Division,them had been examined and enrolled into this study as
of the beginning of 1998. As unrelated cases for this Miles Laboratories, Elkhart, IN, USA) or by an ACR
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Fig. 1. Organization of eNOS and location of the examined polymorphisms. eNOS is located on chromosome 7q35-36 and is comprised of 26
exons (j) and introns (sequences between exons) [10]. The protein has 1203 amino acids. The examined polymorphisms are indicated by arrows.
Kb is kilobase and bp is base pair.
$300 mg/mg. Cases were divided to those with persistent fragment containing the T-786C polymorphism, the for-
ward primer was 59-GCATGCACTCTGGCCTGAAproteinuria and normal serum creatinine (,1.5 mg/dL,
N 5 74) and those with advanced diabetic nephropathy GTG-39, and the reverse was 59-CAGGAAGCTGCC
TTCCAGTGC-39; to amplify a 267-bp fragment con-(N 5 78). The latter group included patients with persis-
tent proteinuria and serum creatinine $1.5 mg/dL (N 5 taining the G894T substitution in exon 7, the forward
primer was 59CTGGAGATGAAGGCAGGAGAC-39,17), as well as with those on dialysis (N 5 14) or with
renal transplant (N 5 47). and the reverse was 59-CTCCATCCCACCCAGTCA
ATC-39.The age and duration of diabetes for controls and
cases with persistent proteinuria (regardless of whether Amplification. Polymerase chain reaction (PCR) was
carried out in a 50 mL volume with 80 ng of genomicserum creatinine was normal or elevated) were deter-
mined as of the year of the last ACR and serum creati- DNA, 50 pmol of each primer, 200 mmol/L dNTP, 1.25
units of displayTAQ FL DNA Polymerase (PGC Scien-nine measurements. The age and duration of diabetes
for cases on dialysis or with renal transplant were calcu- tific Co., Frederick, MD, USA) with 5 mL of 10 3 PCR
buffer containing 15 mmol/L MgCl2 (PGC Scientific Co.).lated as of the year of the first dialysis or transplant.
Initial denaturation was performed at 948C for five min-
Genetic markers and genotyping utes and was followed by 40 cycles consisting of 948C
for one minute, 558C for one minute, and 728C for oneThe organization of eNOS and the locations of the
minute. Amplification was finished with extension atexamined polymorphisms are shown in Figure 1. The
following are brief descriptions of the examined poly- 728C for five minutes.
Blotting. Eight microliters of the PCR-amplified prod-morphisms: (a) a T-786C substitution in the promoter
[23], (b) an insertion-deletion in intron 4 (two alleles: uct were added to 50 mL of denaturing solution [500
mmol/L NaOH, 2.0 mol/L NaCl, 25 mmol/L ethylenedi-the “a-deletion” having 4 repeats of a 27-bp consensus
sequence and the “b-insertion” having 5 repeats) [20], aminetetraacetic acid (EDTA), 0.0001% bromophenol
blue] and transferred onto a nylon membrane placed on(c) a G894T substitution in exon 7 that results in a Glu!
Asp amino acid substitution at codon 298 [24, 25], and a dot-blot apparatus under vacuum. After transfer, the
membrane was immersed for two minutes in a 2 3 so-(d) a (CA) repeat in intron 13, which has 24 alleles [16].
Polymorphisms in the promoter and in exon 7 were dium chloride/sodium citrate solution and was dried for
20 minutes at 808C.determined by allele-specific oligonucleotide (AS) hy-
bridization protocols developed specifically for this Hybridization. To determine the T-786C polymor-
phism, two 17 bp ASO probes were used with the fol-study. The primers were as follows: To amplify a 223-bp
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lowing sequences: 59-CTGGCCGGCTGACCCTG-39 population stratification or selection biases [30]. As
pointed out recently by Altshuler, Kruglyak, and Landerand 59CTGGCTGGCTGACCCTG-39. To determine
the G894T polymorphism, two 17 bp ASO probes were [33], the results of family-based studies are the most
reliable for drawing conclusions about genetic associa-used with the following sequences: 59-GATGAGCC
CCCGAACT-39 and 59GATGATCCCCCGAACT-39. tions. For the TDT, it is necessary to know the genotypes
of both parents as well as their offspring with the speci-Each ASO probe was labeled with the following reaction:
10 mL H2O, 2 mL 10 3 T4 polynucleotide kinase buffer, fied phenotype. In this study, the phenotypes were ad-
vanced nephropathy, proteinuria, and normoalbuminu-1 mL 200 mmol/L dithiothreitol, 3 mL 10 mmol/L ASO,
3 mL 10 mCi/mL (32g)-P-ATP, and 1 mL 10 U/mL T4 ria. Transmission of an allele from heterozygous parents
to offspring is compared with 50%, the expected trans-polynucleotide kinase (Promega, Madison, WI, USA).
After one hour, the reaction was stopped by adding 80 mission in the absence of association, with McNemar’s
Test [30]. Transmission of an allele will exceed 50% ifmL of 25 mmol/L EDTA. The membrane was then put
in a hybridization chamber with 25 mL of hybridization it contributes to the risk of the phenotype. Conversely,
transmission will be less than 50% if the allele reducessolution [tetramethylammonium chloride (TMAC) solu-
tion 3 mol/L, sodium dodecyl sulfate (SDS) 0.6%, EDTA the risk of the phenotype. Offsprings from multiplex as
well as simplex families were used. The analysis was1 mmol/L, Na3PO4 10 mmol/L, Denhardt’s solution 53,
yeast RNA 40 mg/mL] containing 12.5 mL of the labeled repeated using only one offspring per family, and the
conclusions were unchanged.ASO and a 20- to 25-fold excess of unlabeled ASO corre-
sponding to the other allele. The membrane was incu- Transmission of haplotypes can be examined in fami-
lies with the TDT approach. We examined transmissionbated overnight at 528C in a hybridization oven and
then washed 20 minutes in a cold TMAC wash solution of the four haplotypes determined by the T-786C and
a-deletion/b-insertion polymorphisms. Haplotypes could(TMAC 3 mol/L, EDTA 1 mmol/L, Na3PO4 10 mmol/L,
sodium dodecyl sulfate 0.6%) and 20 minutes in a 528C be unambiguously assigned in most families. For the
families with phase unknown haplotypes, conditionalwarmed TMAC wash solution and then exposed for sev-
eral hours to an x-ray film. probabilities of alternative configurations were calcu-
lated using all families, and the most probable haplotypesThe a-deletion/b-insertion in intron 4 was determined
by the following procedure: Forward and reverse primers were assigned. The program Genehunter 2 (version 2.0
beta; website, http: // waldo.wi.mit.edu / ftp / distribution/were used as described previously [20]. The forward
primer was end labeled with (32g)-P-ATP by T4 poly- software/genehunter/gh2) was used to perform the TDT
analysis for both markers separately and haplotypes [34].nucleotide kinase (Promega), and PCR amplification was
performed in 15 mL volume with 20 ng of genomic DNA,
10 pmol of each primer, 200 mmol/L dNTP, 1.5 mmol/L
RESULTS
MgCl, and 0.3 units of TaqGold polymerase (Perkin El-
Case control studymer, Norwalk, CT, USA) with 1.5 mL of 10 3 PCR
buffer. After PCR amplification, 4 mL of the denatured Clinical characteristics of the study groups are summa-
rized in Table 1. Unrelated cases and controls had similarPCR product were loaded onto a 5% polyacrylamide
DNA sequencing gel and resolved electrophoretically. distributions of sex, age, and duration of diabetes. Both
groups of cases had significantly higher blood pressure,Dried gels were exposed to x-ray film for 12 hours.
The CA repeat polymorphism in intron 13 was deter- prevalence of treatment with angiotensin-converting en-
zyme inhibitors, and levels of glycosylated hemoglobinmined according to a previously described protocol [16].
than controls. However, the two groups of cases did
Statistical analysis not differ from each other with regard to any of these
variables, although one had advanced diabetic nephropa-In the case-control comparisons, only unrelated cases
and controls were used. Continuous variables were com- thy and the other had only persistent proteinuria with
normal serum creatinine.pared with t-tests. Genotype and allele frequencies in
controls and the two groups of cases were compared Allele distributions for the four examined eNOS poly-
morphisms are shown in Table 2 according to studyusing standard x2 tests. Odds ratios and their confidence
intervals were calculated according to Rothman [32]. group. The allele frequencies for the polymorphisms in
exon 7 and intron 13 did not vary among the groups,
Family-based test for linkage in the presence so they were not analyzed further. Allele frequencies
of association differed significantly among the study groups for the
polymorphisms in the promoter (x2 5 6.0, 2 d.f., P 5The TDT is a family-based study design that was devel-
oped for testing association between a specified allele 0.05) and in intron 4 (x2 5 10.9, 2 d.f., P 5 0.004). The
C allele of the T-786C polymorphism in the promoterand a disease phenotype. Unlike case-control tests for
association, the TDT is valid even in the presence of and the a-deletion in intron 4 were more frequent in
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Table 1. Clinical characteristics of the study groups
Study groups
Clinical characteristics Controls with Cases with Cases with advanced
at examination normoalbuminuria proteinura nephropathya
Number 195 74 78
% Males 52 42 49
Age years 36.567.6 35.567.3 35.766.5
IDDM duration years 23.766.3 24.969.0 24.566.8
Creatinine mg/dL 0.960.2 1.060.2 —
Systolic BP mm Hg 119615 131616d 139621d
Diastolic BP mm Hg 7269 7969d 81611d
% on ACE inhibitorsb 2 77 75
HbA1C %c 8.261.1 9.261.5d 9.460.9d
Data are mean 6 sd except where percents are shown. Abbreviations are: IDDM, type 1 diabetes; BP, blood pressure; ACE, angiotensin-converting inhibitor.
a Includes 47 patients with renal transplant, 14 on dialysis, and 17 with persistent proteinuria and serum creatinine 1.5 mg/dL or higher
b Individuals on dialysis were excluded for the calculation of the %
c Average of all measurements from period 1991 to 1997
d P , 0.001, cases vs. controls
Table 2. Distribution of alleles (percentage) at the examined eNOS polymorphisms according to the study groups
Study groups
Polymorphisms Controls with Cases with Cases with advanced
Alleles normoalbuminuria proteinuria nephropathy
Number 390 148 156
T-786C in promoter
C 36 35 47
T 64 65 53
Total x2 (2 d.f.) 5 6.0, P 5 0.05
a-deletion/b-insertion in intron 4
a-deletion 14 17 26
b-insertion 86 83 74
Total x2 (2 d.f.) 5 10.9, P 5 0.004
G894T in Exon 7
T 32 26 33
G 68 74 67
Total x2 (2 d.f.) 5 2.0, P 5 0.37
CA repeat in intron 13 (134 bp–190 bp)
C 12 5 8
D 6 13 12
E 11 8 9
F 8 7 7
G 14 15 9
H 7 9 11
I 10 6 8
J 6 13 8
K 5 7 6
Others combined 21 17 22
Total x2 (18 d.f.) 5 16.9, P 5 0.53
Abbreviation: d.f., degrees of freedom.
cases with advanced diabetic nephropathy than in the were few homozygotes for the a-deletion). These results,
expressed as odds ratios, are shown in Table 3. For CCother study groups.
Genotype distributions for the T-786C and the a-dele- homozygotes at the T-786C polymorphism, the odds ra-
tio for advanced diabetic nephropathy was 2.8 (95% CI,tion/b-insertion polymorphisms were in Hardy–Wein-
berg equilibrium in each study group, but they varied 1.4 to 5.6) relative to C/T heterozygotes and TT ho-
mozygotes combined, whereas the corresponding oddssignificantly among the study groups. Cases with ad-
vanced diabetic nephropathy in comparison with the ratio for persistent proteinuria was 1.5, a value not sig-
nificantly different from one. Similarly for carriers ofother two study groups had an excess of CC homozygotes
for the T-786C polymorphism and an excess of heterozy- the a-deletion in intron 4, the odds ratio for advanced
diabetic nephropathy was 2.3 (95% CI, 1.3 to 4.0),gotes for the a-deletion/b-insertion in intron 4 (there
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Table 3. Risk of diabetic nephropathy in carriers of risk alleles at the C-786T and a-deletion/b-insertion polymorphisms of eNOS
Study groups N (%)
Controls with Cases with Cases with
normoalbuminuria proteinuria advanced nephropathy
CC homozygotes 20 (10) 11 (15) 19 (24)
CT/TT 175 (90) 63 (85) 59 (76)
Odds ratio 1.0 1.5 2.8
95% C.I. [reference] (0.7–3.4) (1.4–5.6)
Carriers of a-deletion 51 (26) 23 (31) 35 (45)
Non-carriers 144 (74) 51 (69) 43 (55)
Odds ratio 1.0 1.3 2.3
95% C.I. [reference] (0.7–2.3) (1.3–4.0)
Table 4. Transmission of T-786C alleles and a-deletion/b-insertion of eNOS from heterozygous parents to offspring
according to diabetic nephropathy status
Allele transmitted to offspring
Nephropathy status No. of
in offspring (N )a heterozygous parents N (%) N (%) P
T-786C polymorphisms C T
Advanced nephropathy (69) 82 48 (59) 34 (41) 0.12
Proteinuria only (81) 88 41 (47) 47 (53) 0.52
Normoalbuminuria (73) 72 29 (40) 43 (60) 0.10
Heterogeneity x2 (2 d.f.) 5 5.4, P 5 0.068
a-deletion/b-insertion a-deletion b-insertion
Advanced nephropathy (69) 52 34 (65) 18 (35) 0.03
Proteinuria only (81) 51 26 (51) 25 (49) 0.89
Normoalbuminuria (73) 42 15 (36) 27 (64) 0.06
Heterogeneity x2 (2 d.f.) 5 8.2, P 5 0.017
a Number of trios is in parentheses
whereas the odds ratio for proteinuria was 1.3, a value to offspring with advanced diabetic nephropathy (65%,
P 5 0.03) and almost significantly less than 50% to off-not significantly different from 1.
spring with normoalbuminuria (35.7%, P 5 0.06). The
Family-based study and transmission two alleles were transmitted equally to offspring with
disequilibrium testing proteinuria. The analysis was repeated using only one
offspring per family, and the patterns of transmission toThe findings of the case-control comparison were ex-
amined further in a family-based study using the TDT the three groups of offspring remained the same. There
was a statistically significant (P 5 0.04) excess of trans-for association. We examined the segregation of the risk
alleles from heterozygous parents to three phenotypes: mission of the a-deletion allele to offspring with ad-
vanced diabetic nephropathy (data not shown).offspring with advanced diabetic nephropathy, those
with persistent proteinuria but normal serum creatinine, The transmission of the four eNOS haplotypes defined
by the two polymorphisms was also examined in theand those without diabetic nephropathy but a long dura-
tion of diabetes (Table 4). families (Table 5). The C/a-deletion haplotype was
transmitted from heterozygous parents more frequentlyTransmission of the C allele of the T-786C polymor-
phism in the promoter from heterozygous parents varied (74%) to offspring with advanced diabetic nephropathy
than nontransmitted (26%, P 5 0.004), whereas the T/somewhat according to study group but not significantly
(heterogeneity x2 5 5.4, 2 d.f., P 5 0.068). Transmission b-insertion haplotype was transmitted less frequently
(41%) than nontransmitted (59%, P 5 0.12). Transmis-was greater than 50% to offspring with advanced diabetic
nephropathy and less than 50% to offspring with protein- sion of these two haplotypes from heterozygous parents
to offspring with normoalbuminuria was the reverse ofuria and offspring without nephropathy, but none of
these departures was significant by McNemar’s test. that to offspring with advanced diabetic nephropathy.
There was no distortion of the transmission of theseTransmission of the a-deletion allele in intron 4 from
heterozygous parents, on the other hand, varied signifi- haplotypes to offspring with proteinuria and normal se-
rum creatinine. The two remaining haplotypes, the rarecantly according to study group (heterogeneity x2 5 8.2,
2 d.f., P 5 0.017). It was significantly greater than 50% T/a-deletion and the C/b-insertion, were transmitted
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Table 5. Transmission of haplotypes formed by T-786C alleles and 36], the time from the onset of proteinuria to the progres-
a-deletion/b-insertion at eNOS from heterozygous parents to
sion to ESRD varies enormously among individuals [36–offspring according to nephropathy status
38]. Thus, genes may have an impact on the risk of
Transmitted to nephropathy by contributing to susceptibility to ne-offspring
No. of phropathy or by influencing its rate of progression. To
heterozygous Yes No
determine whether polymorphisms in eNOS contributeHaplotypes parents N (%) N (%) P
to the variation in progression rates, susceptibility to
Offspring with advanced nephropathy
nephropathy, or both, the cases were divided into twoC/a-deletiona 38 28(74) 10(26) 0.004
T/a-deletion 5 2(40) 3(60) 0.65 groups according to the severity of nephropathy for com-
C/b-insertion 46 21(46) 25(54) 0.56 parison with controls without nephropathy. Cases were
T/b-insertion 71 29(41) 42(59) 0.12
divided into those with ESRD or impaired renal functionOffspring with proteinuria only
C/a-deletiona 30 17(57) 13(43) 0.47 and those with proteinuria and normal serum creatinine.
T/a-deletion 7 2(29) 5(71) 0.26 Although this classification does not separate patients
C/b-insertion 45 17(38) 28(62) 0.10
precisely by the rate of progression, patients whose ne-T/b-insertion 66 38(58) 28(42) 0.22
Offspring with normoalbuminuria phropathy progressed rapidly would be concentrated in
C/a-deletiona 31 11(35) 20(65) 0.11 the first group, and those whose nephropathy progressed
T/a-deletion 6 2(33) 4(67) 0.41
slowly would be concentrated in the latter. The a-dele-C/b-insertion 49 22(45) 27(55) 0.48
T/b-insertion 60 38(63) 22(37) 0.04 tion allele in intron 4 of eNOS was specifically associated
a Risk allele with the group of cases with advanced diabetic nephropa-
thy. This result for diabetic nephropathy is consistent
with findings in other complex disorders in which the
influence of genetic determinants appears particularly
from heterozygous parents approximately 50% of the strong in the earliest or most severe phenotypes [27–29].
time to offspring, regardless of their nephropathy status. The mechanisms responsible for the association be-
The a-deletion in intron 4 occurs almost exclusively on tween the a-deletion allele of eNOS and the risk of ad-
chromosomes that also carry the C allele in the promoter, vanced diabetic nephropathy are not known at present.
and the rare T/a-deletion chromosomes are too few to However, low NO levels caused by a defect in NO syn-
determine their association with disease. The C allele, thesis may play a role. A recently published study dem-
on the other hand, occurs with nearly equal frequency onstrated that carriers of the a-deletion allele have 20%
on a neutral as well as the risk haplotype. This can ac- lower plasma levels of the metabolites of NO than non-
count for the weaker association of this allele with ne- carriers [39]. In the rat model, decreased renal NO pro-
phropathy (Table 2) and the fact that CC homozygotes duction accelerates the progression of diabetic nephrop-
but not heterozygotes were at a significantly increased athy, presumably through mechanisms such as increased
risk of advanced nephropathy (Table 3). The haplotype renal vascular tone and potentiation of angiotensin II
results point clearly to the a-deletion polymorphism as effects [9, 40]. There have been no human studies charac-
the strongest marker of disease risk. Either the a-deletion terizing renal hemodynamics in individuals who are car-
itself or a mutation in linkage disequilibrium with it con- riers of the a-deletion allele. In our study, none of the
tributes to the risk of advanced nephropathy. clinical characteristics summarized in Table 1 varied sig-
nificantly between carriers and noncarriers of the a-dele-
tion allele (data not shown).
DISCUSSION
Two alternative molecular mechanisms may be hy-
In this study, we found an association between poly- pothesized to account for the association between the
morphisms in the gene encoding for endothelial NO syn- a-deletion allele and the risk of advanced diabetic ne-
thase and the development of advanced diabetic ne- phropathy. The first assumes that the a-deletion/b-inser-
phropathy in patients with IDDM. The excess risk of tion itself plays a role in tissue-specific regulation of
advanced diabetic nephropathy was specifically associ- eNOS expression. The mechanisms involved may be re-
ated with the a-deletion allele in intron 4 of this gene, lated to the importance of intron structure in the splicing
which is coupled almost exclusively with the 2786C al- of immature RNA to mature RNA or to the presence
lele in the promoter. The latter allele seems to be associ- of enhancer sequences within this intron. The fact that
ated with diminished promoter activity of eNOS [23]. the consensus sequence involved in the polymorphism
The following is a discussion of possible mechanisms in intron 4 is not found in introns of other genes suggests
that could account for these findings. that this sequence does not play a major role in regula-
In type 1 diabetes, proteinuria develops in approxi- tion of gene functions. However, a somewhat homolo-
mately one third of the patients. Although virtually all gous sequence (14 bp) is located in an exon–intron
boundary within the human b-adrenergic receptor ki-cases of proteinuria ultimately progress to ESRD [35,
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nase gene. This raises the possibility that this sequence gression of proteinuria to ESRD. A prospective study
may be involved in the splicing of mRNA. Clearly, fur- is needed to address this issue.
ther studies on the role of the a-deletion/b-insertion in Third, the magnitude of the impact of the a/deletion
intron 4 on expression of eNOS are required. allele on susceptibility to advanced diabetic nephropathy
The second explanation of the association is that the and the generalizability of our findings are uncertain. For
a-deletion has no biological function, but is in linkage example, because our cases with advanced nephropathy
disequilibrium with another biologically important DNA were prevalent cases, it is likely that they have experi-
sequence difference in eNOS or a gene in very close enced high mortality, and this may have reduced the
proximity. We examined three polymorphisms other magnitude of the association. Furthermore, our study
than the a-deletion/b-insertion polymorphism. Two (one was conducted in Caucasians with type 1 diabetes, so it
in exon 7 and the other in intron 13) were not associated is not clear whether our findings can be generalized to
with diabetic nephropathy, and the association of the other races or to patients with type 2 diabetes.
third (the T-786C polymorphism in the promoter) pro- Finally, although the focus of this study was to examine
ved to be secondary to linkage disequilibrium with the genetic susceptibility to diabetic nephropathy associated
a-deletion in the haplotype analysis using the TDT. How- with eNOS polymorphisms, one cannot overlook suscep-
ever, we did not search for other sequence differences tibilities determined by other genes [41], as well as a role
in linkage disequilibrium with the a-deletion. This will of environmental factors in the development of advanced
require sequencing all the exons and introns of eNOS, diabetic nephropathy [42, 43].
the promoter region, as well as the unknown flanking
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